Akio Mori

Akio Mori

Auto-generated profile, based on publicly available information

Akio Mori

Blood Disorders Center, Aiiku Hospital, Sapporo, Japan

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2007 in International Immunology
Verified
Journal Article
Open access
PDF file
AMAkio Mori
Akio Mori
KOKoji Ogawa
Koji Ogawa
KSKoichiro Someya
Koichiro Someya
YKYuichi Kunori
Yuichi Kunori
DNDaisuke Nagakubo
Daisuke Nagakubo
OKOsamu Kaminuma
Osamu Kaminuma
The effects of selective CC chemokine receptor (CCR)-3 antagonists on antigen-induced leukocyte accumulation in the lungs of mice adoptively transferred with in vitro-differentiated Th1 and Th2 were investigated. Inhalation of antigen by mice injected with Th1 and Th2 initiated the migration of T cells themselves into the lungs. Subsequently, neutrophils massively accumulated in Th1-transferred mice, whereas eosinophil infiltration was specifically induced by Th2. CCR3 antagonists, SB-297006 and/or SB-328437, suppressed antigen-induced accumulation of Th2 as well as eosinophils in the lungs, whereas they failed to affect Th1-mediated airway inflammation. Not only Th2 and eosinophil infiltration but also cellular mobilization in Th1-transferred mice was attenuated by an anti-CC chemokine ligand-11 antibody. CCR3 antagonists reduced chemokine production in the lungs of mice transferred with Th2 but not Th1, suggesting that down-regulation of chemokine synthesis is involved in the selective inhibition of Th2-mediated eosinophil infiltration by CCR3 antagonists.

1 November 1999 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
AMAkio Mori
Akio Mori
OKOsamu Kaminuma
Osamu Kaminuma
KMKeiji Miyazawa
Keiji Miyazawa
KOKoji Ogawa
Koji Ogawa
HOHirokazu Okudaira
Hirokazu Okudaira
KAKazuo Akiyama
Kazuo Akiyama
Involvement of p38 mitogen-activated protein (MAP) kinase in human T cell cytokine synthesis was investigated. p38 MAP kinase was clearly induced in human Th cells activated through the TCR. SB203580, a highly selective inhibitor of p38 MAP kinase, inhibited the induction of p38 MAP kinase in human Th cells. Major T cell cytokines, IL-2, IL-4, IL-5, and IFN-γ, were produced by Der f 2-specific Th clones upon stimulation through the TCR. IL-5 synthesis alone was significantly inhibited by SB203580 in a dose-dependent manner, whereas the production of IL-2, IL-4, and IFN-γ was not affected. The proliferation of activated T cells was not affected. IL-5 synthesis of human Th clones induced upon stimulation with rIL-2, phorbol ester plus anti-CD28 mAb, and immobilized anti-CD3 mAb plus soluble anti-CD28 mAb was also suppressed by SB203580 in the same concentration response relationship. The results clearly indicated that IL-5 synthesis by human Th cells is dependent on p38 MAP kinase activity, and is regulated distinctly from IL-2, IL-4, and IFN-γ synthesis. Selective control of IL-5 synthesis will provide a novel treatment devoid of generalized immune suppression for bronchial asthma and atopic dermatitis that are characterized by eosinophilic inflammation.

1 March 2006 in Cardiology
Verified
Journal Article
Closed access
PDF file
HKHiroe Kanamori
Hiroe Kanamori
YTYutaka Tsutsumi
Yutaka Tsutsumi
AMAkio Mori
Akio Mori
TKTakahito Kawamura
Takahito Kawamura
SOShinji Obara
Shinji Obara
NMNobuo Masauzi
Nobuo Masauzi
We report 3 cases of reduced cardiac function with complications in non-Hodgkin’s lymphoma patients who were treated with rituximab. Patients experienced reduced cardiac functions after the administration of rituximab; there was no evidence of any preceding infusion reactions. Reticulin fiber was observed diffusely in cardiac muscles. Transforming growth factor-β levels were elevated after the administration of rituximab. We believe that continuous elevation of transforming growth factor-β may promote the growth of reticulin fiber in cardiac muscles. Reduction in cardiac functions is a severe complication that must be considered when rituximab is administered.

14 February 2020 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
PDF file
SUShinichi Ueno
Shinichi Ueno
THTaku Hatano
Taku Hatano
AOAyami Okuzumi
Ayami Okuzumi
SSShinji Saiki
Shinji Saiki
YOYutaka Oji
Yutaka Oji
NHNobutaka Hattori
Nobutaka Hattori
Objective: To investigate the oxidized albumin ratio, which is the redox ratio of human nonmercaptalbumin (HNA) to serum albumin (%HNA), as a biomarker in idiopathic Parkinson’s disease (iPD) and related neurodegenerative disorders.Methods: This prospective study enrolled 216 iPD patients, 15 patients with autosomal recessive familial PD due to parkin mutations (PARK2), 30 multiple system atrophy (MSA) patients, 32 progressive nuclear palsy (PSP) patients, and 143 healthy controls. HNA was analyzed using modified high‐performance liquid chromatography and was evaluated alongside other parameters.Results: iPD and PARK2 patients had a higher %HNA than controls (iPD vs. controls: odds ratio (OR) 1.325, P < 0.001; PARK2 vs. controls: OR 1.712, P < 0.001). Even iPD patients at an early Hoehn & Yahr stage (I and II) showed a higher %HNA than controls. iPD patients had a higher %HNA than MSA and PSP patients (iPD vs. MSA: OR 1.249, P < 0.001, iPD vs. PSP: OR 1.288, P < 0.05). When discriminating iPD patients from controls, %HNA corrected by age achieved an AUC of 0.750; when discriminating iPD patients from MSA and PSP patients, an AUC of 0.747 was achieved. Furthermore, uric acid, an antioxidant compound, was decreased in iPD patients, similar to the change in %HNA.Interpretation: %HNA was significantly increased in iPD and PARK2 patients compared with controls, regardless of disease course and severity. Oxidative stress might be increased from the early stages of iPD and PARK2 and play an important role in their pathomechanisms.

Verified
Journal Article
Open access
PDF file
MSMayumi Saeki
Mayumi Saeki
TNTomoe Nishimura
Tomoe Nishimura
NKNoriko Kitamura
Noriko Kitamura
THTakachika Hiroi
Takachika Hiroi
AMAkio Mori
Akio Mori
OKOsamu Kaminuma
Osamu Kaminuma
Bronchial asthma is a chronic disease characterized by reversible airway obstruction, mucus production, and bronchial hyperresponsiveness (BHR). Although Th2 cell-mediated eosinophilic inflammation is an important disease mechanism in the majority of patients with bronchial asthma, recent studies suggest the possible development of Th2-independent airway inflammation and BHR. These non-Th2 endotype patients seem to consist of multiple subgroups, and often do not respond to inhaled corticosteroids. Therefore, to understand the pathogenesis of asthma, it is important to characterize these non-Th2 subgroups. Recently, we demonstrated that Th9 cells induce eosinophil infiltration and eosinophil-independent BHR, and Th9 cells-mediated BHR may be resistant to glucocorticoid. In this review, we summarize the contribution of several T cell subsets in the development of bronchial asthma and introduce our recent study demonstrating Th9 cell-mediated and eosinophil-independent BHR.

13 March 2022 in British Journal of Haematology
Verified
Journal Article
Open access
AMAkio Mori
Akio Mori
MOMasahiro Onozawa
Masahiro Onozawa
STShihori Tsukamoto
Shihori Tsukamoto
TITakashi Ishio
Takashi Ishio
EYEmi Yokoyama
Emi Yokoyama
TKTakeshi Kondo
Takeshi Kondo
Data on the response to the COVID-19 vaccine in patients with myeloid malignancy, who are at severe risk in case of infection, have not emerged. In a study of 69 patients with myeloid malignancies, including 46 patients with acute myeloid leukaemia (AML) and 23 patients with myelodysplastic syndrome (MDS), anti-spike SARS-CoV-2 antibody titres were measured 3 months after the second mRNA-based vaccination. Seroconversion rates for AML and MDS were 94.7% and 100% respectively, with no significant difference from healthy controls (HCs). Patients with MDS showed a significantly lower antibody titre than that in HCs or AML patients. In AML patients, the antibody titres were comparable to those in HCs when treatment was completed, but lower in patients under maintenance therapy. The response to COVID-19 vaccine appears to be related to disease and treatment status. Patients with myeloid malignancies may be more responsive to vaccines than patients with lymphoid malignancies.